Fintel reports that on April 20, 2023, HC Wainwright & Co. reiterated coverage of Allogene Therapeutics (NASDAQ:ALLO) with a Buy recommendation.
Analyst Price Forecast Suggests 261.92% Upside
As of April 6, 2023, the average one-year price target for Allogene Therapeutics is $18.06. The forecasts range from a low of $6.06 to a high of $36.75. The average price target represents an increase of 261.92% from its latest reported closing price of $4.99.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Allogene Therapeutics is $4MM, an increase of 1,539.92%. The projected annual non-GAAP EPS is -$2.83.
What are Other Shareholders Doing?
DFEOX - U.s. Core Equity 1 Portfolio - Institutional Class holds 78K shares representing 0.05% ownership of the company. In it's prior filing, the firm reported owning 74K shares, representing an increase of 6.01%. The firm decreased its portfolio allocation in ALLO by 23.20% over the last quarter.
IWM - iShares Russell 2000 ETF holds 1,838K shares representing 1.27% ownership of the company. In it's prior filing, the firm reported owning 1,740K shares, representing an increase of 5.30%. The firm decreased its portfolio allocation in ALLO by 44.30% over the last quarter.
SCHB - Schwab U.S. Broad Market ETF holds 48K shares representing 0.03% ownership of the company. In it's prior filing, the firm reported owning 38K shares, representing an increase of 19.44%. The firm decreased its portfolio allocation in ALLO by 14.16% over the last quarter.
URTY - ProShares UltraPro Russell2000 holds 6K shares representing 0.00% ownership of the company. In it's prior filing, the firm reported owning 5K shares, representing an increase of 17.38%. The firm decreased its portfolio allocation in ALLO by 18.89% over the last quarter.
FBIOX - Biotechnology Portfolio holds 1,557K shares representing 1.08% ownership of the company. In it's prior filing, the firm reported owning 1,319K shares, representing an increase of 15.28%. The firm decreased its portfolio allocation in ALLO by 17.15% over the last quarter.
What is the Fund Sentiment?
There are 387 funds or institutions reporting positions in Allogene Therapeutics. This is a decrease of 39 owner(s) or 9.15% in the last quarter. Average portfolio weight of all funds dedicated to ALLO is 0.22%, an increase of 28.27%. Total shares owned by institutions increased in the last three months by 3.49% to 125,180K shares. 
The put/call ratio of ALLO is 1.93, indicating a bearish outlook.
Allogene Therapeutics Background Information
(This description is provided by the company.)
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR Tâ˘) therapies for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of 'off-the-shelf' CAR T cell therapy candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
